Topics | BioWorld
Regulatory front. Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity.... BioWorld. Today's news. Analysis and data insight. Clinical. Data Snapshots. Deals and M&A.
Sen. Cassidy: Time for US FDA to reclaim its Orange Book duties
Oct 2, 2024 · It’s well past time for the U.S. FDA to end its silence on what device patents can be listed in the Orange Book as part of a drug-device combination product, Sen. Bill Cassidy (R-La.) said in an Oct. 1 letter that took FDA Commissioner …
Kent Imaging looking to raise $25M for wound care devices
Oct 1, 2024 · Kent Imaging Inc. is looking to raise $25 million in a series B financing round to expand the use of its imaging device for measuring wound and tissue oxygenation, and to support the launch of a new product, Pierre Lemire, CEO, told BioWorld. Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their ...
Biopharma financings surge to $86.2B in 2024, with $8.7B in …
Oct 4, 2024 · Biopharma financings continued to outperform over the first nine months of 2024, hitting $86.2 billion, a 75% increase from the $49.35 billion raised during the same period in 2023. September alone saw a significant boost from the prior month, with financings more than doubling to $8.7 billion from $3.5 billion in August.
US FDA clears Cobenfy, first new schizophrenia drug in decades
Sep 27, 2024 · The FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the first to act via a novel mechanism for the serious psychiatric disorder in over 50 years, finally expanding the treatment options beyond dopamine-targeted therapies.
VHB-937, a TREM2-binding MAb with efficacy in a broad range of ...
Mar 11, 2024 · It has been previously demonstrated that TREM2 is extensively shed during chronic neuroinflammation, which hiders its function, while TREM2 activation enhances effector functions of microglia.
High-affinity ACP3 ligands for prostate cancer treatments
June 11, 2024. Philochem AG has discovered an ultra-high-affinity ACP3 ligand – OncoACP3 – isolated through the screening of DNA-encoded chemical libraries for the potential treatment of prostate cancer. BioWorld Science Conferences Cancer. By the numbers: US leads charge of cell and gene therapies. U.S. biotechs and regulators ushered in ...
Genentech’s new multiple sclerosis treatment reduces admin time
Sep 16, 2024 · Genentech’s newly approved multiple sclerosis (MS) injection takes about 10 minutes to administer, dramatically reducing the four to six hours required by its intravenous predecessor. The U.S. FDA approved the humanized monoclonal antibody Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for relapsing MS and primary progressive MS on Sept. 13.
Stop interleukin-11 to age better and live longer - BioWorld
Jul 24, 2024 · Although there is no single answer, scientists at Duke-National University of Singapore (NUS) have shown in mice that interleukin-11 (IL-11) promoted aging. Blocking it improved health and lifespan. BioWorld Science Aging Endocrine/metabolic Inflammatory Antibody. Regulatory snapshots, including global drug submissions and approvals, clinical ...
Chemistry Nobel awarded for 3D protein design, prediction work
Oct 9, 2024 · David Baker, Demis Hassabis and John Jumper share the 2024 Nobel Prize in Chemistry for their contributions to the science of protein structure. David Baker was awarded half the prize “for computational protein design,” according to the Royal Swedish Academy of Sciences. Hassabis and Jumper shared the other half “for protein structure prediction.”